Key result
This review highlights pitfalls in assays for detecting anti-interferon antibodies in multiple sclerosis and emphasizes the need for individualized medicine over standardized regimens.
This review emphasizes the complexities of detecting anti-interferon antibodies in multiple sclerosis and advocates for individualized therapeutic approaches.
Answers are grounded in this paper and cite their sources.
Assay pitfalls warrant cautious interpretation of anti-interferon antibodies in MS; leaves open optimal individualized regimens pending validation.
This review discusses type I interferon (IFN) immunogenicity with focus on methods of detection of anti-IFN antibodies in patients treated with human recombinant IFN-β. Pitfalls involved in the clinical use of various types of assays for binding antibodies and neutralizing antibodies against IFN-β are presented, and the widely held distinction between binding antibodies and neutralizing antibodies is questioned both in terms of detection and clinical importance. The article also addresses important bioavailability and pharmacokinetic issues occurring with prolonged use of protein drugs. The rationale for individualized or personalized medicine, ie, optimizing therapies according to individual needs rather than using standardized trial-and-error regimens to all patients, is highlighted.
No takes yet. Share an insight, caveat, or question.
Klaus Bendtzen (2010) conducted a review in Multiple Sclerosis. Human recombinant IFN-β was evaluated. This review highlights pitfalls in assays for detecting anti-interferon antibodies in multiple sclerosis and emphasizes the need for individualized medicine over standardized regimens.
Synapse has enriched 10 related papers. Consider them for comparative context: